Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Authors:
- Milind Y. DesaiMDMilind Y. Desai
- Kathy WolskiKWKathy Wolski
- Anjali OwensAOAnjali Owens
- Jeffrey B. GeskeJGJeffrey B. Geske
- Sara SaberiSSSara Saberi
- Andrew WangAWAndrew Wang
- Mark SherridMSMark Sherrid
- Paul C. CremerPCPaul C. Cremer
- Neal K. LakdawalaNLNeal K. Lakdawala
- Albree Tower-RaderATAlbree Tower-Rader
- David FerminDFDavid Fermin
- Srihari S. NaiduSNSrihari S. Naidu
Top Cited Papers
Open Access
- 13 May 2025
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (19) , 1378-1390
Abstract
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov ; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.Keywords
Funding Information
- Bristol Myers Squibb Foundation
This publication has 42 references indexed in Scilit:
- Results of Ventricular Septal Myectomy and Hypertrophic Cardiomyopathy (from Nationwide Inpatient Sample [1998–2010])The American Journal of Cardiology, 2014
- Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general populationEuropean Heart Journal, 2014
- Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract ObstructionCirculation, 2013
- Survival After Alcohol Septal Ablation for Obstructive Hypertrophic CardiomyopathyCirculation, 2012
- 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic CardiomyopathyJACC, 2011
- Long-Term Survival in Patients With Resting Obstructive Hypertrophic CardiomyopathyJACC, 2011
- Current Effectiveness and Risks of Isolated Septal Myectomy for Hypertrophic Obstructive CardiomyopathyThe Annals of Thoracic Surgery, 2008
- Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2005
- Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic CardiomyopathyCirculation, 2005
- Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 PatientsCirculation, 1964